Peptide inhibition of BCL6 led to xenografted human CML cells failing to initiate leukemia in transplant recipients, and selectively eradicated CD34+CD38− LSCs in patient-derived CML samples [83]. The gene discussed is BCL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.